Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA

BJU International

Volumn 94, Issue 1, 2004, Pages 47-50

  Parsons, J Kellogg ^a   Brawer, Michael K ^b   Cheli, Carol D ^c   Partin, Alan W ^a   Djavan, Robert ^d  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Northwest Prostate Institute   (United States)

^c BAYER CORPORATION   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biopsy; Cancer; Complexed; Prostate; PSA; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RECEIVER OPERATING CHARACTERISTIC; REDUCTION; ROC CURVE; TASK PERFORMANCE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; UNNECESSARY PROCEDURES;

EID: 3242809698     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04899.x     Document Type: Article

References (23)

1. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003; 349: 335-42
2. Smith DS, Carvalhal GF, Mager DE, Bullock AD, Catalona WJ. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol 1998; 160: 1734-8
3. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5
4. Okihara K, Fritsche HA, Ayala A, Johnston DA, Allard WJ, Babaian RJ. Can complexed prostate specific antigen and prostatic Volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol 2001; 165: 1930-6
5. Horninger W, Cheli CD, Babaian RJ et al. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2-4 nanograms per milliliter. Urology 2002; 60 (Suppl. 1): 31-5
6. Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 806-12
7. Haese A, Dworschack RT, Partin AW. Percent free prostate specific antigen in the total prostate specific antigen 2-4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4-10 ng./ml. range. J Urol 2002; 168: 504-8
8. Roehl KA, Anterior JA, Catalona WJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6-4.0 ng./ml. range. J Urol 2002; 168: 922-5
9. Mitchell ID, Croal BL, Dickie A, Cohen NP, Ross I. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol 2001; 165: 1549-53
10. Brawer MK, Meyer GE, Letran JL et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 1998; 52: 372-8
11. Miller MC, O'Dowd GJ, Partin AW, Veltri RW. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. Urology 2001; 57: 1105-11
12. Djavan B, Remzi M, Zlotta AR et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology 2002; 60 (Suppl. 1): 4-9
13. Brawer MK, Cheli CD, Neaman IE et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
14. Partin AW, Brawer MK, Bartsch G et al. Complexed prostate specific antigen improves specificity for prostate cancer detection, results of a prospective multicenter clinical trial. J Urol 2003; 170: 1787-91
15. Okegawa T, Noda H, Nutahara K, Higashihara E. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology 2000; 55: 700-4
16. Brawer MK. Clinical usefulness of assays for complexed prostate-specific antigen. Urol Clin North Am 2002; 29: 193-203
17. Naya Y, Stamey TA, Cheli CD et al. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen? Urology 2002; 60 (Suppl. 1): 36-41
18. Lein M, Kwiatkowski M, Semjonow A et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 2003; 170: 1175-9
19. Jung K, Stephan C, Elgeti U et al. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer? Int J Cancer 2001; 93: 759-65
20. Ellison L, Cheli CD, Bright S, Veltri RW, Partin AW. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening. Urology 2002; 60 (Suppl. 4A): 42-6
21. Cheli CD, Levine RL, Cambetas DR, Kolker JD, Roberts SB. Age-related reference ranges for complexed prostate-specific antigen and complexed/total prostate-specific antigen ratio: results from East Texas Medical Center Cancer Institute screening campaign. Urology 2002; 60 (Suppl. 1): 53-9
22. Berger AP, Cheli C, Levine RL, Klocker H, Bartsch G, Horninger W. Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/ml. Urology 2003; 62: 84-9
23. Martin B, Cheli C, Pollard S et al. Similar age-specific PSA, complexed PSA, and percent cPSA levels among African-American and white men of southern Louisiana. Prostate-specific antigen. Urology 2003; 61: 375-9